Table 5.

Association between estimated lifetime applications of genital powder and risk of ovarian cancer (borderline and invasive combined)

Lifetime number of applicationsaAll cases (N = 7,587)Nonmucinous cases (N = 6,361)
Controls (%)Cases (%)ORb (95% CI)Cases (%)ORb (95% CI)
Never users6,175 (76)5,384 (71)1.004,472 (70)1.00
Quartile 1509 (6)534 (7)1.14 (1.00–1.31)467 (7)1.18 (1.02–1.36)
Quartile 2512 (6)541 (7)1.23 (1.08–1.41)456 (7)1.22 (1.06–1.41)
Quartile 3497 (6)542 (7)1.22 (1.07–1.40)457 (7)1.22 (1.06–1.40)
Quartile 4486 (6)586 (8)1.32 (1.16–1.52)509 (8)1.37 (1.19–1.58)
Ptrendc0.170.17
  • aAge-specific 25th, 50th, and 75th percentile cutoff points are 612, 1,872, and 5,400 for participants < 40 years old; 612, 2,160, and 7,200 for 41–50 years; 720, 3,600, and 10,800 for 51–60 years; 1,440, 5,760, and 14,440 for 61–70; 840, 7,200, and 18,000 for > 70 years.

  • bORs were estimated using conditional logistic regression conditioned on 5-year age groups and adjusted for age (continuous), oral contraceptive duration (never use, <2, 2–<5, 5–<10, or ≥10 years), parity (0, 1, 2, 3, or 4+ children), tubal ligation history (no or yes), BMI (quartiles), race/ethnicity (non-Hispanic White, Hispanic White, Black, Asian, or other).

  • cTrend excludes never users.